Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLANS: Cetuximab-800CW for Penile Carcinoma Surgery
NCT05376202Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cetuximab-IRDye 800CW in penile squamous cell carcinoma (PSCC), sponsored by University Medical Center Groningen. Primary endpoint: Spot to Background Ratio at 2 years. Started Mar 2022; status: completed.
02
Drugs
cetuximab-IRDye 800CW
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT05376202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05376202.